Sheila Ranganath, Ph.D.

VP, Biology

Sheila is a passionate scientist who is experienced in all parts of the drug discovery process from target ID and validation to the clinic.  She is a drug discovery professional who has taken a modality agnostic approach to targets throughout her career, progressing antibodies, small molecules and engineered protein therapeutics to candidate selection and preclinical development.

Prior to joining LifeMine, Sheila was Director, Discovery Oncology at Merck. During this time, she built a topflight team of biologists which characterized the immunological mechanism of action of oncology drugs singly, and in combination with checkpoint inhibitors, in the tumor microenvironment, impacting nearly all projects in the Merck Discovery Oncology pipeline. In addition, Sheila led several multi-disciplinary teams to develop drug candidates including two small molecules and two engineered protein therapeutics, which are in pre-clinical development.

Before joining Merck, she spent ten years in positions of increasing responsibility at Wyeth/Pfizer, Ironwood Pharmaceuticals and Enumeral Biomedical working in the Cardiovascular/Metabolic, Inflammation, and Immuno-Oncology therapeutic areas discovering antibody, peptide, and small molecule drug candidates.

Sheila earned a B.A. in Molecular and Cellular Biology from U.C. Berkeley and a Ph.D in Immunology from Washington University with Professor Kenneth Murphy. She was a postdoctoral fellow at Harvard Medical School where she investigated the mechanisms of VDJ Recombination and Non-Homologous End Joining in lymphomagenesis with Professor Frederick Alt.